NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Molecular Precision in Coronary Heart Disease Detection
This article highlights the limitations of traditional cardiovascular risk assessment and introduces Cardio Diagnostics Holdings' epigenetic and genetic tests that aim to detect coronary heart disease (CHD) with higher sensitivity, addressing a critical blind spot where about 50% of CHD patients lack traditional risk factors.
Traditional risk assessment methods (cholesterol, blood pressure, etc.) have an average sensitivity of 39%, and about 50% of individuals with CHD do not present with traditional risk factors, leading to missed diagnoses and preventable cardiac events.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics that examine how genes are expressed and regulated at the molecular level, providing a more complete picture of heart disease development.
It means that conventional risk calculators fail to identify CHD in 61% of cases, leaving many individuals who appear healthy at risk of undetected heart disease and preventable heart attacks.
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is the company developing molecular precision tests for coronary heart disease detection.
The latest news and updates are available in the company’s newsroom at https://ibn.fm/CDIO.
BioMedWire is a communications platform that focuses on Biotechnology, Biomedical Sciences, and Life Sciences sectors, and it published the article about Cardio Diagnostics.